Malignant peripheral nerve sheath tumor cell invasion is facilitated by Src and aberrant CD44 expression

GLIA

Volumn 42, Issue 4, 2003, Pages 350-358

  Su, Weiping ^a   Sin, Mihaela ^a   Darrow, Andrea ^a   Sherman, Larry S ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

CD44; Malignant peripheral nerve sheath tumor; Neurofibromatosis; Ras; Src

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; HERMES ANTIGEN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NEUROFIBROMIN; PROTEIN TYROSINE KINASE;

ARTICLE; CANCER INCIDENCE; CANCER INVASION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME MECHANISM; GENE ACTIVATION; GENE ACTIVITY; GENE EXPRESSION; GENE LOSS; GENE TARGETING; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; ONCOGENE RAS; PERIPHERAL NERVE; TUMOR CELL;

ANTIGENS, CD44; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE KINASE KINASE 1; NEOPLASM INVASIVENESS; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSES; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SRC-FAMILY KINASES; TUMOR CELLS, CULTURED;

EID: 0037782147     PISSN: 08941491     EISSN: None     Source Type: Journal    
DOI: 10.1002/glia.10206     Document Type: Article

References (65)

1. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. 1992. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356: 713-715.
2. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ. 1999. Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 274:8335-8343.
3. Cichowski K, Jacks T. 2001. NF1 tumor suppressor gene function: narrowing the GAP. Cell 104:593-604.
4. Combaret V, Gross N, Lasset C, Frappaz D, Beretta-Brognara C, Philip T, Beck D, Favrot MC. 1997. Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma. Eur J Cancer 33:2101-2105.
5. DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC, Lowy DR. 1992. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69:265-273.
6. DeClue JE, Heffelfinger S, Benvenuto G, Ling B, Li S, Rui W, Vass WC, Viskochil D, Ratner N. 2000. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest 105:1233-1241.
7. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. 1986. Malignant peripheral nerve sheath tumors. A clinico-pathologic study of 120 cases. Cancer 57:2006-2021.
8. Ellerbroek SM, Halbleib JM, Benavidez M, Warmka JK, Wattenberg EV, Stack MS, Hudson LG. 2001. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res 61: 1855-1861.
9. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. 2002. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39:311-314
10. Ferner RE, Gutmann DH. 2002. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 62:1573-1577.
11. Ghosh BC, Ghosh L, Huvos AG, Fortner JG. 1973. Malignant schwannoma. A clinicopathologic study. Cancer 31:184-190.
12. Glover TW, Stein CK, Legius E, Anderson LB, Brereton A, Johnson S. 1991. Molecular and cytogenetic analysis of tumors in von Recklinghausen neurofibromatosis. Genes Chromosomes Cancer 3:62- 70.
13. Gross N, Balmas Bourloud K, Brognara CB. 2000. MYCN-related suppression of functional CD44 expression enhances tumorigenic properties of human neuroblastoma cells. Exp Cell Res 260:396- 403.
14. Guha A, Lau N, Huvar I, Gutmann D, Provias J, Pawson T, Boss G. 1996. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene 12:507-513.
15. Hackel PO, Zwick E, Prenzel N, Ullrich A. 1999. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 11:184-189.
16. Halling KC, Scheithauer BW, Halling AC, Nascimento AG, Ziesmer SC, Roche PC, Wollan PC. 1996. p53 expression in neurofibroma and malignant peripheral nerve sheath tumor. An immunohistochemical study of sporadic and NF1-associated tumors. Am J Clin Pathol 106:282-288.
17. Hernández-Alcoceba R, del Peso L, Lacal JC. 2000. The Ras family of GTPases in cancer cell invasion. Cell Mol Life Sci 57:65-76.
18. Hofmann M, Rudy W, Gunthert U, Zimmer SG, Zawadzki V, Zoller M, Lichtner RB, Herrlich P, Ponta H. 1993. A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res 53:1516-1521.
19. Irby RB, Yeatman TJ. 2000. Role of Src expression and activation in human cancer. Oncogene 19:5636-5642.
20. Jamal HH, Cano-Gauci DF, Buick RN, Filmus J. 1994. Activated ras and src induce CD44 overexpression in rat intestinal epithelial cells. Oncogene 9:417-423.
21. Kim HA, Ling B, Ratner N. 1997. Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase. Mol Cell Biol 17:862-872.
22. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. 2000. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77:25-79.
23. Kogerman P, Sy MS, Culp LA. 1996. CD44 protein levels and its biological activity are regulated in Balb/c 3T3 fibroblasts by serum factors and by transformation with the ras but not with the sis oncogene. J Cell Physiol 169:341-349.
24. Kong M, Mounier C, Dumas V, Posner BI. 2003. EGF-induced DNA synthesis: key role for Src phosphorylation of the docking protein Gab2. J Biol Chem 278:5837-5844.
25. Kourea HP, Cordon-Cardo C, Dudas M, Leung D, Woodruff JM. 1999. Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. Am J Pathol 155:1885-1891.
26. Kwatra MM, Bigner DD, Cohn JA. 1992. The ligand binding domain of the epidermal growth factor receptor is not required for receptor dimerization. Biochim Biophys Acta 1134:178-181
27. Lamb RF, Hennigan RF, Turnbull K, Katsanakis KD, MacKenzie ED, Birnie GD, Ozanne BW. 1997. AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol Cell Biol 17:963-976.
28. Legius E, Marchuk DA, Collins FS, Glover TW. 1993. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet 3:122- 126.
29. Li H, Velasco-Miguel S, Vass WC, Parada LF, DeClue JE. 2002. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res 62:4507-4513.
30. Liapis H, Marley EF, Lin Y, Dehner LP. 1999. p53 and Ki-67 proliferating cell nuclear antigen in benign and malignant peripheral nerve sheath tumors in children. Pediatr Dev Pathol 2:377-384.
31. Lothe RA, Slettan A, Saeter G, Brogger A, Borresen AL, Nesland JM. 1995. Alterations at chromosome 17 loci in peripheral nerve sheath tumors. J Neuropathol Exp Neurol 54:65-73.
32. McCarron KF, Goldblum JR. 1998. Plexiform neurofibroma with and without associated malignant peripheral nerve sheath tumor: a clinicopathologic and immunohistochemical analysis of 54 cases. Mod Pathol 11:612-617.
33. Menon AG, Anderson KM, Riccardi VM, Chung RY, Whaley JM, Yandell DW, Farmer GE, Freiman RN, Lee JK, Li FP, Barker D, Ledbetter D, Kleider A, Martuza R, Gusella J, Seizinger B. 1990. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Reckling-hausen neurofibromatosis. Proc Natl Acad Sci U S A 87:5435-5439.
34. Merzak A, Koocheckpour S, Pilkington GJ. 1994. CD44 mediates human glioma cell adhesion and invasion in vitro. Cancer Res 54:3988-3992.
35. Missbach M, Jeschke M, Feyen J, Muller K, Glatt M, Green J, Susa M. 1999. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 24:437-449.
36. Morioka N, Tsuchida T, Etoh T, Ishibashi Y, Otsuka F. 1990. A case of neurofibrosarcoma associated with neurofibromatosis: light microscopic, ultrastructural, immunohistochemical and biochemical investigations. J Dermatol 17:312-316.
37. Naor D, Sionov RV, Ish-Shalom D. 1997. CD44: structure, function, and association with the malignant process. Adv Cancer Res 71: 241-319.
38. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg AE, Louis DN. 1999. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol 155:1879-1884.
39. Perry A, Roth KA, Banerjee R, Fuller CE, Gutmann DH. 2001. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. Am J Pathol 159: 57-61.
40. Perry A, Kunz SN, Fuller CE, Banerjee R, Marley EF, Liapis H, Watson MA, Gutmann DH. 2002. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol 61:702-709.
41. Price JT, Tiganis T, Agarwal A, Djakiew D, Thompson EW. 1999. Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3′-kinase and phospholipase C-dependent mechanism. Cancer Res 59:5475-5478.
42. Rasmussen SA, Overman J, Thomson SA, Colman SD, Abernathy CR, Trimpert RE, Moose R, Virdi G, Roux K, Bauer M, Rojiani AM, Maria BL, Muir D, Wallace MR. 2000. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1. Genes Chromosomes Cancer 28:425-431.
43. Sangueza OP, Requena L. 1998. Neoplasms with neural differentiation: a review. Part II. Malignant neoplasms. Am J Dermatopathol 20:89-102.
44. Sawada S, Florell S, Purandare SM, Ota M, Stephens K, Viskochil D. 1996. Identification of NF1 mutations in both alleles of a dermal neurofibroma. Nat Genet 14:110-112.
45. Serra E, Puig S, Otero D, Gaona A, Kruyer H, Ars E, Estivill X, Lazaro C. 1997. Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. Am J Hum Genet 61:512-519.
46. Serra E, Rosenbaum T, Nadal M, Winner U, Ars E, Estivill X, Lazaro C. 2001. Mitotic recombination effects homozygosity for NF1 germline mutations in neurofibromas. Nat Genet 28:294-296.
47. Sheela S, Riccardi VM, Ratner N. 1990. Angiogenic and invasive properties of neurofibroma Schwann cells. J Cell Biol 111:645-653.
48. Sherman L, Sleeman J, Dall P, Hekele A, Moll J, Ponta H, Herrlich P. 1996. The CD44 proteins in embryonic development and in cancer. Curr Top Microbiol Immunol 213:249-269.
49. Sherman L, Jacoby LB, Lampe J, Pelton P, Aguzzi A, Herrlich P, Ponta H. 1997. CD44 expression is aberrant in benign Schwann cell tumors possessing mutations in the neurofibromatosis type 2, but not type 1, gene. Cancer Res 157:4889-4897.
50. Sherman L, Sleeman JP, Hennigan RF, Herrlich P, Ratner N. 1999. Overexpression of activated neu/erbB2 initiates immortalization and malignant transformation of immature Schwann cells in vitro. Oncogene 18:6692-6699.
51. Sherman LS, Atit R, Rosenbaum T, Cox AD, Ratner N. 2000a. Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. J Biol Chem 275:30740-30745.
52. Sherman LS, Rizvi TA, Karyala S, Ratner N. 2000b. CD44 enhances neuregulin signaling by Schwann cells. J Cell Biol 150:1071-1084.
53. Skuse GR, Kosciolek BA, Rowley PT. 1989. Molecular genetic analysis of tumors in von Recklinghausen neurofibromatosis: loss of heterozygosity for chromosome 17. Genes Chromosomes Cancer 1:36- 41.
54. Sordillo PP, Helson L, Hajdu SI. 1981. Malignant schwannoma - clinical characteristics, survival, and response to therapy. Cancer 47:2503-2509.
55. Talamonti MS, Roh MS, Curley SA, Gallick GE. 1993. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 91:53-60.
56. Tatsuka M, Ota T, Yamagishi N, Kashihara Y, Wada M, Matsuda N, Mitsui H, Seiki M, Odashima S. 1996. Different metastatic potentials of ras- and src-transformed BALB/c 3T3 A31 variant cells. Mol Carcinog 15:300-308.
57. Weg-Remers S, Ponta H, Herrlich P, Konig H. 2001. Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J 20:4194-4203.
58. Wells A. 1999. EGF receptor. Int J Biochem Cell Biol 31:637-643.
59. Werner MH, Nanney LB, Stoscheck CM, King LE. 1988. Localization of immunoreactive epidermal growth factor receptors in human nervous system. J Histochem Cytochem 36:81-86.
60. White HR. 1971. Survival in malignant schwannoma. An 18-year study. Cancer 27:720-729.
61. Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL. 1998. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 42:351-360.
62. Yan N, Ricca C, Fletcher J, Glover T, Seizinger BR, Manne V. 1995. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype. Cancer Res 55:3569-3575.
63. Yu X, Sharma KD, Takahashi T, Iwamoto R, Mekada E. 2002. Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling. Mol Biol Cell 13:2547-2557.
64. Zhang M, Singh RK, Wang MH, Wells A, Siegal GP. 1996. Epidermal growth factor modulates cell attachment to hyaluronic acid by the cell surface glycoprotein CD44. Clin Exp Metastasis 14:268-276.
65. Zhang M, Wang MH, Singh RK, Wells A, Siegal GP. 1997. Epidermal growth factor induces CD44 gene expression through a novel regulatory element in mouse fibroblasts. J Biol Chem 272:14139-14146.